VISTECH grant for Anadis
Tuesday, 01 July, 2008
Melbourne's Anadis (ASX: ANX) has been awarded a significant grant from VISTECH for its alimentary mucositis treatment.
The grant is one of only three awarded from VISTECH, a bi-national fund granted by the Victorian and the Israeli Governments, and was awarded through a competitive process including a vigorous scientific assessment.
The US$500,000 grant was awarded to Anadis and its Israeli collaborator Maya BioTech. The money will be used to help fund a clinical trial of polyclonal antibodies, which is expected to take between 18-24 months.
Anadis is predicting to be able to launch a commercial product in as little as two years.
Gastro-intestinal and oral mucositis is a significant side effect of cancer therapy.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
